• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

80.44 +0.04 (+0.05%)
Streaming Delayed Price Updated: 11:21 AM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 205,833
Open 79.75
Bid (Size) 80.43 (200)
Ask (Size) 80.49 (200)
Prev. Close 80.40
Today's Range 79.75 - 80.76
52wk Range 46.81 - 93.42
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
Today 7:30 EDT
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+2.8%
+2.8%
1 Month
-4.4%
-4.4%
3 Month
+18.8%
+18.8%
6 Month
+17.8%
+17.8%
1 Year
+70.1%
+70.1%

More News

Read More
News headline image
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
Via The Motley Fool
Topics Earnings
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗
August 11, 2026
Via Chartmill
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
August 16, 2026
Via The Motley Fool
News headline image
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗
August 14, 2026
Via The Motley Fool
News headline image
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
August 10, 2026
Via MarketBeat
Topics Earnings
News headline image
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 03, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗
August 02, 2026
Via The Motley Fool
News headline image
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
July 13, 2026
Via MarketBeat
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
July 09, 2026
Via Chartmill
News headline image
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 02, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
July 02, 2026
Via The Motley Fool
News headline image
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 01, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗
May 13, 2026
Via MarketBeat

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 80.44
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 08/26/26 11:21 AM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.91B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap